Technology

DelAQUA Platform

Robust and Tunable block copolymer platform enables delivery of highly loaded micelles with one, two, and even up to four drugs in a single micelle.

POLY(2-OXAZOLINE) BLOCK COPOLYMER (POx)

WATER INSOLUBLE BLOCK

WATER SOLUBLE BLOCK

Easily tunable chemistries and block lengths

to match with water-insoluble compound

Rapid screening of POx polymer libraries

Modeling to identify best polymer match

Unmatched solubilization enhancement

Drug loading up to 50% or more

Broadest range of formulation options

Polyoxazoline Copolymer Nanoparticle (POx)

30-60 nanometer

Insoluble compound solubilized within particle core protected by hydrophilic particle corona

DelAQUA Solves the BBB: Increased drug delivery to the brain with POx Copolymers

POx micelles deliver more Palbociclib in Medulloblastoma Models

Palbociclib and BT44 Case Studies

Accumulation of Palbociclib in serum, forebrain and tumor was higher for POx micelles than free drug (IP injection)

POx-Palbo had ~1.5x higher Cmax in forebrain and tumor

Palbo-POx had 1.8x and 2.3x higher AUC in forebrain and tumor, respectively, and 2X serum exposure

Lim et al, Sci Adv. 8, eabl5838 (2022)

POx micelles deliver more BT44 to brain via SC injection

POx micelles deliver 12x more BT44 to brain via subcutaneous injection than PG solubilized drug

The relative increase of BT44 concentration using POx-BT44 vs PG-BT44 was approximately two times higher in brain (b) than in plasma (a)

POx-BT44 was remarkably safer than PG-BT44 formulation as measured by behavioral parameters

Haider et al., Biomacromolecules 2023, 24, 4348

DelAQUA’s Poly(2-Oxazoline) Platform Enables Co-Delivery of Multiple Drugs to Target Site for Synergistic Effects and Improved Therapeutic Outcomes

DelAQUA’s High Dose Paclitaxel (PTX) Co-Loaded with Immunomodulating CSF1R Inhibitor (PLX)

Co-Loading enables high dose delivery of synergistic combinations at the desired ratios to the site of disease

Combination of high dose paclitaxel and immunomodulator in POx micelles drastically reduces tumor growth in aggressive TNBC models

DelAQUA’s Poly(2-Oxazoline) platform allows co-delivery of a wide range drugs for targeting multiple disease pathways

DelAQUA’s Dual-Chemotherapy Enabling Micelles: Paclitaxel and Cisplatin Pro-Drug

Combination Loaded micelles improve the delivery (C-max and AUC) to tumors of both drugs

Combination Loaded micelles (Red) outperform single drug and non-coloaded micelles (Blue) in tumor suppression and survival

Co-loading improves micelle stability in vivo, slowing release, and increasing delivery efficiency

DelAQUA POx Polymers improve Oral Bioavailability of both P-glycoprotein substrate and non P-glycoprotein (P-gp) substrate drugs

Improved Bioavailability of Non-Pgp Substrates (Collaboration with Boehringer-Ingelheim)

In collaborative study with Boehringer-Ingelheim (Germany), POx polymers increased Cmax 38-fold, AUC 6-fold over their standard microsuspension formulation

Achieved near quantitative drug exposure through POx mediated drug solubilization

Creates new opportunities for easy to swallow liquids and capsules for pediatric and geriatric products

Oral POx Delivers Paclitaxel with Dramatically Higher Oral Bioavailability and Higher Tumor Accumulation Compared to IV Injection in Mice

DelAQUA's POx formulations increase oral bioavailability of paclitaxel to nearly 97% in mice

POx polymers enable convenient oral administration of critical oncology drugs with improved tumor accumulation

POx formulations have demonstrated physical stability for months as a solution and years as a lyophilized powder

DelAQUA Polymers are near ubiquitous stabilizers of drug nanocrystal suspensions

Bottom Up Preparation Enables Inhalation Delivery of Remdesivir

Increases drug solubility in suspension up to 10,000-fold

Low foaming of excipients yield consistent output of fine particles from nebulizer over dosing period

Output is comparable to other nanocrystal inhalable formulations on the market

Top-Down Milling improves Dissolution Profile, Reducing Toxicity

DelAQUA Milled Nanocrystals (red) improve dissolution profile, reducing C-max and mitigating toxicity

Formulations easily stored frozen and readily scalable for large batches

Comparable AUC achieved with very low intersubject variability

DelAQUA’s Versatile Polymer Platform Enables Delivery and Improves Efficacy

Increases solubility of poorly soluble compounds up to 100,000-fold! Platform compatible with over 80% of drugs tested
Enables dosing solution for intravenous, oral, inhalation, intraperitoneal, nasal, ocular, topical, and subcutaneous administration

POx platform overcomes classic barriers to drug delivery in the BBB and GI tract

DelAQUA’s High Dose Paclitaxel out performs Abraxane for tumor suppression and survival across multiple mouse models for cancer

DelAQUA’s platform allows for the co-encapsulation and delivery of up to four drugs in the same micelle for synergistic effects against disease targets in vivo

POx-stabilized nanocrystals demonstrate outstanding physical stability in aqueous suspension

PHARMACEUTICALS

Technology

DelAQUA Platform

DelAQUA Solves the BBB: Increased drug delivery to the brain with POx Copolymers

DelAQUA’s Poly(2-Oxazoline) Platform Enables Co-Delivery of Multiple Drugs to Target Site for Synergistic Effects and Improved Therapeutic Outcomes

DelAQUA POx Polymers improve Oral Bioavailability of both P-glycoprotein substrate and non P-glycoprotein (P-gp) substrate drugs

DelAQUA Polymers are near ubiquitous stabilizers of drug nanocrystal suspensions

PHARMACEUTICALS

Technology

DelAQUA Platform

​

PHARMACEUTICALS